Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
| Autor: | Ribera, Jose-Maria, Genescà, Eulàlia, Ribera Salas, Jordi, Universitat Autònoma de Barcelona |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Blinatumomab
CD3 T cell acute lymphoblastic leukemia Review Acute lymphoblastic leukemia CD19 03 medical and health sciences 0302 clinical medicine Antigen blinatumomab medicine B-cell precursor B cell biology lcsh:RC633-647.5 business.industry Hematopoietic stem cell lcsh:Diseases of the blood and blood-forming organs Hematology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer research biology.protein bispecific antibodies Antibody Bispecific antibodies business 030215 immunology medicine.drug |
| Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Therapeutic Advances in Hematology, Vol 11 (2020) Therapeutic Advances in Hematology |
| ISSN: | 2040-6215 2040-6207 |
| DOI: | 10.1177/2040620720919632 |
| Popis: | Bispecific T-cell engaging antibodies are constructs engineered to bind to two different antigens, one to a tumor-specific target and the other to CD3-positive T cells or natural killer (NK) cells. Blinatumomab engages CD19 and CD3, performing effective serial lysis. The clinical development program in acute lymphoblastic leukemia (ALL) includes clinical trials in relapsed or refractory (R/R) patients and in B-cell precursor (BCP) ALL patients with measurable residual disease. Several trials are currently being conducted in de novo BCP-ALL, either in induction, consolidation, or before or after hematopoietic stem cell transplant. Combination with other targeted therapies or with other immunotherapeutic approaches are also underway. Several strategies are aimed to optimize the use of blinatumomab either by overcoming the mechanisms of resistance (e.g. inhibition of PD-1/PD-L1) or by improvements in the route of application, among others. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|